Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
02/15/18
DUBLIN , Feb. 15, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted the submission of the landmark IMPACT study data to the European Medicines Agency (EMA) as part of a type II variation to support an expanded label for Trelegy Ellipta in
02/07/18
Theravance Biopharma Together with Janssen will Jointly Develop and Commercialize TD-1473, a Novel, Potent, Orally Administered and Intestinally Restricted pan-Janus Kinase (JAK) Inhibitor Theravance Biopharma Eligible to Receive up to $1 Billion in Potential Payments, Including $100 Million
01/29/18
FDA Assigns PDUFA Target Action Date of November 13, 2018 DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Jan. 29, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that the U.S.
11/28/17
DUBLIN , Nov. 28, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted the filing of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration ( FDA ) for the use of Trelegy Ellipta, the triple combination therapy
11/21/17
DUBLIN , Nov. 21, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 8:00 a.m. ET .
11/16/17
Launch of Trelegy Ellipta in Europe Expected Before End of Year DUBLIN , Nov. 16, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that the European Commission has granted marketing authorization for Trelegy Ellipta, the triple combination
11/13/17
Filing Supported by Positive Results from Two Pivotal Phase 3 Efficacy Studies and One 12-Month Phase 3 Safety Study DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Nov. 13, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") and Mylan N.V.
11/07/17
Inflection Points for Key Development Programs Anticipated Throughout 2018 Trelegy Ellipta Launch Expected by Year-End 2017 DUBLIN , Nov. 7, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today reported financial results for the third
11/01/17
Presentations Highlight 24-Hour Serial Spirometry Subgroup Findings from Two Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire and COPD Assessment Test Results DUBLIN, Ireland , HERTFORDSHIRE, England and PITTSBURGH , Nov.
11/01/17
Company Plans to Add 30 Highly Skilled Jobs in Dublin over Next Two Years DUBLIN , Nov. 1, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today announced the opening of a new corporate office in Dublin , further establishing the Company's presence in